BMS-986142
- Generic Name
- BMS-986142
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H30F2N4O4
- CAS Number
- 1643368-58-4
- Unique Ingredient Identifier
- PJX9GH268R
- Background
BMS-986142 is under investigation in clinical trial NCT02880670 (Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT02880670
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT02843659
- Locations
- 🇺🇸
Arthritis And Osteoporosis Associates, Pa, Freehold, New Jersey, United States
🇺🇸Acme Research, Llc, Orangeburg, South Carolina, United States
🇺🇸West Tennessee Research Institute, Jackson, Tennessee, United States
The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT02832180
- Locations
- 🇺🇸
Covance Evansville Clinical Research Unit, Evansville, Indiana, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 508
- Registration Number
- NCT02638948
- Locations
- 🇺🇸
Precision Research Organization, Miami Lakes, Florida, United States
🇺🇸Vizae Clinical Trials Management, Pembroke Pines, Florida, United States
🇺🇸Integral Rheumatology & Immunology Specialists, Plantation, Florida, United States
Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 118
- Registration Number
- NCT02257151
- Locations
- 🇺🇸
Wcct Global, Llc, Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.